Ocuphire Pharma Results Presentation Deck
RM
12
Percent of Subjects (%)
Secondary Endpoint: % of Subjects Returning to Baseline PD by Mydriatic Agent
Subjects Dilated with Phenylephrine had a Faster Response to Nyxol than Tropicamide/Paremyd
100%
80%
60%
40%
20%
0%
Placebo n=55
Nyxol n=56
Placebo n=55 Nyxol n=56
0.5
6%
2%
MIRA-2 Phase 3 Trial
Study Eye (mITT Population)
Percent of Subjects Returning to ≤ 0.2 mm of Baseline by Mydriatic Agent
Phenylephrine
1
4%
46%
p<0.0001
p<0.0001
p<0.0001
JUI
1.5
11%
79%
2
18%
82%
p<0.0001 p<0.0001 p<0.05
Source: MIRA-2 TLR table # 14.2.1.4 (mITT)
3
29%
86%
4
44%
84%
Time Post-Treatment with Nyxol/Placebo (Hours)
6
56%
86%
Percent of Subjects (%)
100%
80%
60%
40%
20%
0%
Placebo (n=36)
Nyxol (n=38)
Tropicamide or Paremyd
Placebo (n=36) Nyxol (n=38)
0.5
0%
0%
1
0%
0%
1.5
0%
5%
p<0.05
2
0%
24%
p<0.0001
p<0.001
11
3
0%
71%
4
8%
79%
Time Post-Treatment with Nyxol/Placebo (Hours)
p<0.0001
6
28%
97%
Ocuphire
PHARMAView entire presentation